FEMY — what changed in the latest 10-Q
A section-by-section comparison of FEMY's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-08-14 vs the prior 10-Q · 2026-05-08
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +75 | −137 | 0 | 0 |
| Market risk (Item 3) | Text added/removed | 0 | −116 | ~19 | 1 |
| Controls & procedures | Text added/removed | 0 | −116 | ~19 | 1 |
| Legal proceedings | Text added/removed | 0 | −116 | ~19 | 1 |
| Risk factors | Restated in full this quarter | +20 | 0 | 0 | 0 |
| Other information | Text added/removed | 0 | −115 | ~19 | 1 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-08-14
Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K filed with the U.S. Securities and Exch…
We are a leading biomedical innovator, addressing significant unmet needs in women’s health worldwide, with a broad patent-protected portfolio of disruptive, accessible, in-office therapeutic and diagnostic products. The Company is a U.S. manufacturer that has received global regulatory approvals fo…
FemBloc® permanent birth control is a revolutionary first-in-class non-surgical solution which involves minimally-invasive placement of a patented delivery system for precise delivery of our proprietary synthetic tissue adhesive (blended polymer) into both fallopian tubes simultaneously. Over time, …
We are a woman-founded and led company with an expansive, internally created intellectual property portfolio with approximately 228 issued patents globally, in-house chemistry, manufacturing, and controls (CMC) and device manufacturing capabilities and proven ability to develop products with commerc…
Text removed vs the prior filing · source: 10-Q · 2026-05-08
Item 3Quantitative and Qualitative Disclosures About Market Risk38
Item 2Unregistered Sales of Equity Securities and Use of Proceeds42
This Quarterly Report on Form 10-Q contains forward-looking statements. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” …
• our ability to obtain additional financing to fund commercialization of our products and fund our operations;
• our ability to obtain additional financing to fund the U.S. clinical development of our U.S. product candidate FemBloc® permanent birth control;
Market risk (Item 3)
Text removed vs the prior filing · source: 10-Q · 2026-05-08
Item 2Unregistered Sales of Equity Securities and Use of Proceeds42
The accompanying notes are an integral part of these condensed unaudited financial statements.
The accompanying notes are an integral part of these condensed unaudited financial statements.
Issuance of common stock in connection with at-the-market offering, net of issuance costs
Issuance of common shares in payment of 2023 convertible note interest, including related parties
Controls & procedures
Text removed vs the prior filing · source: 10-Q · 2026-05-08
Item 2Unregistered Sales of Equity Securities and Use of Proceeds42
The accompanying notes are an integral part of these condensed unaudited financial statements.
The accompanying notes are an integral part of these condensed unaudited financial statements.
Issuance of common stock in connection with at-the-market offering, net of issuance costs
Issuance of common shares in payment of 2023 convertible note interest, including related parties
Legal proceedings
Text removed vs the prior filing · source: 10-Q · 2026-05-08
Item 2Unregistered Sales of Equity Securities and Use of Proceeds42
The accompanying notes are an integral part of these condensed unaudited financial statements.
The accompanying notes are an integral part of these condensed unaudited financial statements.
Issuance of common stock in connection with at-the-market offering, net of issuance costs
Issuance of common shares in payment of 2023 convertible note interest, including related parties
Risk factors
Text added vs the prior filing · source: 10-Q · 2026-08-14
This Quarterly Report on Form 10-Q contains forward-looking statements. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” …
our ability to obtain additional financing to fund commercialization of our products and fund our operations;
our ability to obtain additional financing to fund the U.S. clinical development of our U.S. product candidate FemBloc® permanent birth control;
our ability to obtain U.S. Food and Drug Administration (FDA) approval for our U.S. product candidate, FemBloc for permanent birth control;
our ability to successfully grow sales of FemaSeed® intratubal insemination in the U.S.;
Other information
Text removed vs the prior filing · source: 10-Q · 2026-05-08
The accompanying notes are an integral part of these condensed unaudited financial statements.
The accompanying notes are an integral part of these condensed unaudited financial statements.
Issuance of common stock in connection with at-the-market offering, net of issuance costs
Issuance of common shares in payment of 2023 convertible note interest, including related parties
Issuance of common stock in connection with at-the-market offering, net of issuance costs
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice